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We compared the characteristics of adenosine deami-
nases (ADs) (E.C. 3 .5.4.4.) in squamous cell carcinoma 
and normal human epidermis. Increased specific activ-
ity (per mg protein) of AD was observed in squamous 
cell carcinoma compared with that of the normal epider-
mis. In normal hu man epidermis most of the AD existed 
as a large form (M. 300,000-350,000, type A) . Squa-
mous cell carcinoma of the skin was characterized by a 
high proportion of small-form (M. 30,000- 40,000, type 
C) AD. The proportion of the small-form enzyme varied 
from tumor to tumor. Comparison of the large-form AD 
from squamous cell carcinoma to that from normal epi-
dermis revealed that both enzymes were similar in rel-
ative substrate specificity, K"' va lues for adenosine, pH 
optima, heat stability pattern, isoelectric point, and sen-
sitivity to inhibition by coformycin, a tight binding in-
hibitor of AD . However, the low molecular weight of 
AD from squamous cell carcinoma was less heat stable 
than that from the large-molecular-weight form . 
Increased AD activity and the high proportion of the 
small form of AD might be significant features of squa-
mous cell carcinoma of the skin. 
Ade nosine deaminase (AD) (E.C. 3.5.4.4.) cata lyzes t he hy-
drolytic deam ination of eit her aden osine or deoxyadenosine to 
produce inosine a nd deoxy inosin e respective ly. It has been 
suggested t hat AD has a crit ical role in t he proliferation a nd 
maturation of certain types of m a mma lia n cells . The m atura-
t ion of T ly mphocytes is inhibited by a n AD inhibito r, while 
that of B lymphocytes is less inhibited [1 ,2]. During t he mat-
ura tion o f m on ocytes, AD activity increases while other en -
zymes of t he purine nucleot ide salvage pathway a re not a ltered 
[3]. In leukemia wit h T cell markers o r null cell m a rkers a nd 
pre -B-cell leukemia , AD activity is e levated [4- 6] . In Sezary 's 
syndrome a nd adult T-cell leukemia which is a recently char -
acterized leukemia in J apan [7], AD activity is elevated [8,9], 
while in B-cell chronic leukemia t he en zym e activity is not 
elevated [6, 10] . N ot only the activity but a lso t h e molecula r 
character istics may cha n ge wi t h cell prolife ra tion a nd matura-
t ion [3,11] . 
AD activity in psoriatic involved epidermis is increased com-
pared to uninvolved epidermis a nd n ormal epiderm is [1 2]. In 
addition , it was shown in pig epidermis t ha t 2 types of AD are 
presen t [13,14] . 
In t he epide rmis , t he re la t ionship be tween cell differentiation 
a nd prolifera t ion a nd AD activi ty rema ins to be determined. 
Thus we investigated the d ifference in the cha racteris tics of 
AD in squa mous cell carcinoma a nd n orma l huma n epidermis. 
Manuscript received October 25, 1983; accepted for publication 
October 30, 1984. 
Supported in part by grant 56770502 from the Ministry of Education, 
J apan. 
Reprint requests to: Hiroko Koizum i, M.D., Depart ment of Derma-
tology, Hokkaido University, School of Medicine, Kita 15 Nishi 7, Kita-
ku, Sapporo, Japan. 
Abbreviations: 
AD: adenosine deaminase 
199 
MATERIALS AND METHODS 
Squamo!L5 Cell Carcinoma of the Skin 
Three squamous cell carcinoma specimens were obtained from t he 
P lastic Surgery Memorial Hospi tal and the Department of Dermatol-
ogy, Hokkaido University Hospital immediate ly afte r surgical ctissec-
t ion. Diagnostic evaluation of a ll surgical samples was performed by 
t he Department of Dermatology, Hokkaido University School of Med-
icine. None of the patients had been t reated with antimetabolite or by 
radiotherapy for at least 1 month. The sites of tumors were shin, hip, 
and sole. The patients were 48- to 69-year-old males. 
N ormal Hum an Skin 
Six normal human skin specimens were obta ined t hrough Sapporo 
National Hospita l and t he Department of Ort hopectic Surgery, Hok-
kaido University Hospital immectiately fo llowing leg amputation. T hree 
patients were male and 3 were female 10- 52 years of age. The causes 
of the amputations were bone or soft t issue tumors; t he leg skin had 
no involvement of the tumor or secondary changes such as edema. 
E nzyme Prepara tion 
Squamous cell carcinomas were minced and washed 3 t imes with 
saline to remove blood. Normal human skin slices taken with a Castro-
viejo keratome adjusted to 0.2 mm were rinsed in saline. Fresh t issues 
were immediately homogenized in 50 mM phosphate buffer, pH 7.1, 
wit h an Ikemoto RKI all glass homogenizer at a concentration of 1 g 
wet weight t issue to 5 ml buffer. The homogenates were centrifuged fo r 
10 min at 1500 g. The supernatant was ult racentrifuged fo r 90 min at 
105,000 g. The following procedures for part ial purification of t he 
enzyme were performed according to the method of Ma and Fisher [1 5] 
as described previously [14]. except that the gel fil t ration chromatog-
raphy was performed on a Sephadex G-200 column (1.6 X 92 em) . 
Briefly, the supernatant following the ultracentri f~ugation was t reated 
with 30- 65% (W / V) ammonium sulfate, chromatographed on a Seph-
adex G-200 column and t he fractions wit h AD activity were pooled. 
Determination of Enzyme Activity 
The enzyme activity was measured by a moctification of Kalcker 's 
technique [16] as described previously [14]. A unit of enzyme activity 
was defined as the amount of enzyme that produced a decrease in 
absorbance at 265 nm of 0.010/ min under t he condit ions described 
[ 17]. T he amount of protein was determined according to Lowry et at 
[18], employing bovine serum albumin as a standard. 
l soelectric Focu.5ing 
Isoelectric focusing was perfo rmed as described previously [1 4]. A 
1% solution of H3PO, in 60% sucrose (W / V) was layered over t he 
anode followed by a 40% to 0% (W / V) sucrose gradient (approximately 
110 ml) conta ining 1% ampholine ampholytes, pH 3.5- 10 (LKB No. 
1809-10) . The samples were desalted on a Sephadex G-25 column and 
were applied near the middle of the gradient column. A 2% solution of 
ethanolamine was layered onto the top of t he gradient. T he samples 
were electro focused at 500 V at 4 ·c for 48 h, t hen 1.2-ml fractions from 
t l}e bottom of the column were collected and the pH and enzyme 
activity determined. 
Chemical<; 
Sephadex G-200, Sephadex G-25M (Pharmacia Column PD-10), and 
blue dextran were purchased from Pharmacia J apan (Tokyo). Cofor-
mycin was a generous gift from Dr. Umezawa of t he Institute of 
Microbia l Chemist ry (Tokyo). 2' -Deoxyadenosine was purchased from 
PL Biochemicals Inc. (Milwaukee, Wisconsin) . All other chemicals 
were obta ined from Wako Pure Chemical Indust. (Osaka) . All buffers 
were freshly prepared before each experiment. 
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RESULTS 
Adenosine Deaminase Activity in Normal Human Epidermis 
and Squamous Cell Carcinoma 
AD activi ty of the ultracentrifuged supernatant is shown in 
Fig 1. The mean activity in the normal epiderm is is calculated 
as 2.77 units/mg protein (range, 2.27- 3.30, n = 6). Although 
the enzyme activities in squamous cell carcinomas varied from 
tumor to tumor (3.89, 5.04, 9.96 units/mg protein), they were 
shown to be elevated in the tumor as compared with the normal 
epidermis. 
Tumor Specific Variants of Adenosine Deaminase 
The tissue samples were analyzed for the molecular weight 
distribution of AD by gel fil t ration of Sephadex G-200 column 
chromatography. The results of typical experiments are shown 
in Fig 2. The gel fi lt ration showed two peaks of AD. This 
indicates that at least 2 forms of AD are present in human 
epidermis. The molecular weights of each enzyme were about 
300,000- 350,000 (type A) and 30,000-40,000 (type C), respec-
t ively. In normal human epidermis over 90% of the enzyme 
activity eluted with large molecular weight. Therefore the nor-
mal human epidermal AD was revealed to be composed of 
predominant ly type A AD. In all of the squamous cell carcino-
mas of the skin the amount of the small-form AD was markedly 
greater t han from normal human epidermis. The percentage of 
the small-form enzyme varied from tumor to tumor (39-61 %). 
All of the tumors examined were well differentiated squamous 
ce ll carci nomas (Broder's classification, grade 1). The amount 
of type C AD did not correlate wi th the malignant grade of the 
tumor. 
Biochemical Nature of Adenosine Deaminase 
Several enzymatic properties were compared between the 
large-form enzymes from normal human epidermis and squa-
mous cell ca rcinoma, as well as the small-form enzyme in 
squamous cell carcinoma. The gel filtrat ion fractions with the 
highest enzyme activities were combined and were used as the 
enzyme sources. The effect of different concentrations of aden-
osine on the enzyme activities of each AD was investigated. 
The enzyme activities were roughly dose-dependent and the 
maximal effect was observed at around 1 X 10-• M. Lineweaver-
Burk plots revealed that the apparent K, values for adenosine 
of the enzymes were similar (3- 6 X 10-" M) (data not shown) . 
These values did not vary from case to case. Thus the affinity 
toward the substrate was similar. AD can catalyze the deami-
nation of adenosine and deoxyadenosine. Both substrates were 
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FIG 1. Adenosine deaminase activity in normal epidermis a nd squa-
mous cell carcinoma (SCC) of human skin . Each point presents the 
AD activity in 3 SCC a nd 6 normal epidermis. Horizontal bars indicate 
mean AD activity. 
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FIG 2. Normal human epidermal and squamous cell carcinoma AD 
shown by the gel filtration technique. Ammonium su lfate fraction (30-
65%, W / V) was applied to a column of Sephadex G-200 equilibrated 
with 50 mM phosphate buffer, pH 7.1, at 4 ·c, and elution was carried 
out with the same buffer. Two-milliliter fractions were collected and 
aliquots were assayed f01' AD activity. The void volume was determined 
with blue dextran. The protein concentration was measured by UV 
absorbance at 280 nm. The recovery of applied activity was typically 
50- 75 %. AD activity in normal epidermis (a), and in squamous cell 
carcinoma (b). The arrows indicate the position of molecular weight 
markers: 1 = blue dext ran, .2 = aldorase (158,000) , 3 = bovine serum 
albumin (67,000), 4 = trypsin inhibitor (21,400). 
therefore employed to determine relative substrate specificities. 
The final concentration of the substrates was 1 x 10- • M . The 
relative substrate specificity (ratio of activity toward deoxy-
adenosine to that toward adenosine) was about 90% in both 
enzymes (data not shown). No remarkable differences were 
observed. The enzymes had similar pH optima of around 7.0 
(data not shown) . Coformycin, a tight-binding inhibitor of AD, 
inhibited the AD activity strongly [19-22) (Fig 3). Fifty percent 
inhibition of the enzyme activity was obtained at the concen-
tration of 2 X 10- 8 M of coformycin when the substrate, cofor-
mycin, and the enzyme were mixed simultaneously. However, 
after 30-min preincubation of the enzyme and coformycin, 
complete inhibition was obtained at the concentration of 5 x 
10- 9 M . Fig 4 shows several spectrophotometric tracings of AD 
reactions in the presence of various concentrations of cofor-
mycin. In these reactions, the inhibitor, enzyme, and substrate 
were mixed simultaneously. As seen in Fig 4, t here was little 
difference in the very early reaction velocities, regardless of the 
inhibitor concentrations. The difference in the velocities be-
came obvious after a few minutes of the reaction. These phe-
nomena suggest that dissociation of the AD coformycin com-
plex is too slow to contribute free enzyme during the short 
assay period. Thus in the case of the tight-binding inhibitor, 
the association and dissociation reaction may be slow; there-
fore, proper inhibitor constants can be obtained only after long 
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preincubation of t he enzyme and the inhibitor [21]. There were 
no differences in sensitivity to coformycin amonu the ADs 
examined. Thus biochemical natures examined- th: Km value 
for. adenosine, substrate specificity, pH optima, inhibition by 
coformycm- were quite similar between large-form ADs, and 
between the large- and small-form ADs. In addition we could 
not detect any difference in AD from case to case. 
The heat stability of AD was studied (data not shown). The 
enzymes were heated to 56•C and 65 · C. The large-form en-
zymes were relatively stable at 56•C and about 50% of activity 
rem~med after 60-min incubation. At 65 · c, 50% inhibition was 
obtamed after 10-min incubation, and almost all the enzyme 
activity was lost after a 30-min incubation period. The small-
form enzyme had about 30% of the original activity after 30-
rnin incubation at 56•C, and at 65•C no activity remained after 
10-min incubation. The large-form enzymes were shown to be 
more stable than the small-form enzyme at 56 •C and 65•C, the 
difference being more marked at 65 · c . 
Isoelectric focusing revealed that the maximum activity was 
obtained at around pH 4.7 in each enzyme (Fig 5). The isoelec-
tric point of large-form enzyme from normal human epidermis 
was 4.95, that of large-form enzyme from squamous cell carci-
noma was 4.77, that of small-form enzyme from squamous cell 
carcinoma was 4.52. No remarkable differences in isoelectric 
points were detected among the different ADs. 
DISCUSSION 
Adenosine and deoxyadenosine, the substrates of AD, have 
a cytotoxic or cytostatic effect on cells. In pig epidermis, aden-
osine and deoxyadenosine inhibit DNA synthesis without the 
accumulation of cyclic AMP (23]. Thus AD plays a role not 
only in nucleic acid salvage pathway metabolism [24- 26] but 
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FIG 3. Inhibition of AD by coformycin (the large-form AD from 
normal human epidermis) . Cofo rmycin was added in t he reagent mix-
ture simulta neously with adenosine a nd the enzyme (0), or the enzyme 
was preincubated with coformycin for 30 min at 37"C and the assay 
was then started by adding adenosine (0). The final concentration of 
adenosine employed in the enzyme assay was 170 ~M. 
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FIG 4. Spectrophotometric tracings of t he AD reaction in the pres-
ence of co form ycin . The small-form AD was employed. Coformycin 
was added in the reagent mixture simultaneously with adenosine and 
the enzyme. 
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FIG 5. The isoelectric focusing pattern of AD. Two milliliters of a 
desalted sample was applied near the middle of the gradient column. 
After electrofocused, 1.2- ml fractions were collected from the bottom 
of the column. The pH and enzyme activity of each fraction were 
determined. The small-form enzyme from squamous cell carcinoma is 
shown. 
also on cell proliferation maturation and detoxification of t he 
excess adenosine or deoxyadenosine [2,3,27,28]. 
Two cytoplasmic forms of AD are characterized as small 
form (type C, M , 35,000) and large form (type A, M, 200,000) 
[15,29,30]. The intermediate type B (M, 100,000) is usually 
found in the particulate fraction [29] . Type C AD is reported 
to combine with AD-binding protein and is incorporated in t he 
quarternary structure of type A AD (31-33]. The relative 
amount of type A and type C enzyme varies from tissue to 
tissue. Type C AD predominates in tissues such as spleen, 
stomach, erythrocytes, and leukocytes. Type A enzyme predom-
inates in kidney, liver, lung, and skin fibroblasts [29,34]. Free 
binding protein in excess of enzyme is found in kidney, lung, 
and placenta (29,33]. The t issues with relatively high specific 
activity usually possess the type C enzyme except for erythro-
cytes [35] . In some tumor cells, elevated AD activity [4 ,7-9] as 
well as alterations in the ratio of the large and small forms of 
ADs are reported [36 ,37]. In these tumors, such as lung, kidney, 
and colon tumors, the proportion of small-form enzyme is high 
and the enzyme activity is also elevated compared with that in 
normal tissue. The alteration of the molecular forms and t he 
activity of AD are also reported in human monocyte maturation 
and lymphoblast formation [3,11]. 
In this study of the normal human epidermis, the large form 
of AD was shown to be predominant. On the contrary, squa-
mous cell carcinoma of the skin was shown to be characterized 
by a high proportion of the small form of AD and high total 
AD activity. The biochemical nature of the large-form AD from 
normal human epidermis, and the large-form and small-form 
enzymes from squamous cell carcinoma are very similar in t heir 
K"' values for adenosine, substrate specificity, pH optima, in-
hibitiOn by coformycin, and isoelectric points. However, the 
large-form enzyme is more stable at 56 · c and 65·c than is the 
small-form enzyme. It remains to determine whether the alter-
ation of the molecular form and activity of AD is due to the 
transformation or rapid cell proliferation. 
The role of the AD-binding protein remains to be determined. 
The protein has been detected in soluble fractions of human 
lung and kidney [29,33]. Recently this protein has been iden-
tified in membrane fractions of human skin fibroblasts and 
placenta [38,39]. Both preparations have a similar molecular 
weight (110,000), and convert type C AD to type A AD. Trotta 
[39] hypotheses that AD is anchored to the plasma membrane 
through a specific binding protein, which functions to protect 
the mammalian cell from the t.oxic effects of adenosine and 
deoxyadenosine entering from the extracellular space. Free 
binding protein and type A AD are present in the tissues that 
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have low AD activity. Although we could demonstrate that the 
proportion of type C AD is increased in proliferative t issues 
such as squamous cell carcinoma, the analysis of t he amount 
of the binding protein was not investigated. The precise relation 
between AD and its binding protein with epidermal cell prolif-
eration is currently under way in our laboratory. 
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